secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0000950170-23-070935
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo receives FDA Fast Track and Orphan Drug designations for gene therapy LX2020 in PKP2-ACM
--------------------------------------------------------------------------------

- FDA granted Fast Track and Orphan Drug designations for LX2020, an AAVrh10 gene therapy for PKP2-ACM.
- No approved treatments exist for PKP2-ACM, a prevalent genetic cardiovascular disease.
- LX2020 delivers a functional PKP2 gene intravenously to cardiac muscle as a one-time infusion.
- Planned Phase 1/2 HEROIC-PKP2 trial: 52-week, open-label, dose-escalating, multicenter with two cohorts (2.0x10^13 and 6.0x10^13 vg/kg).
- Orphan Drug offers market exclusivity and tax credits; Fast Track enables expedited FDA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017023070935/0000950170-23-070935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017023070935/lxeo-20231218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer